Our academic collaborators’ seminal contributions push the field forward
Our constellation of renowned thinkers and partners
The right collaborators across pharma, biotech and nonprofit
The next generation of scientific leaders in cancer immunotherapy
Stories & Announcements
PICI in the News
Resources for Press
An Immunologist Breaks Down COVID-19
2019 Annual Report
The Parker Institute for Cancer Immunotherapy Awards $2.75 Million to Support Six Early Career Researchers from Leading Research Institutions
Develop breakthrough immune therapies to turn all cancers into curable diseases faster
The driving force behind PICI’s research and operations
Transformative science requires visionary philanthropy
Join us. Change lives.
All researchers have data from their studies. But data means little studied in isolation. Our BioTrust centralizes and standardizes patient samples, assay data and clinical outcomes from our network’s research projects and clinical trials to fuel next-level science. Our deeply comprehensive collection is shared throughout our network so that we’re not only igniting smarter research, but growing our own knowledge base at the same time – providing the foundation to advance discovery in patient diagnosis and treatment.
Transitional Suite Assays
Our experienced professionals have extensive expertise in immuno-oncology patents and provide strategic guidance and advice throughout the process.
Cheryl Selinsky, PhD
Vice President, Research Operations
Associate Director, Biospecimen Acquisition and Operations